PharmNXT brings European Bioprocess Engineering to India with strategic acquisition of DTR
July 28, 2025 | Monday | News
PharmNXT’s acquisition comes at a time when India’s pharmaceutical exports have surged past $30 billion in FY25
image credit- shutterstock
In a landmark development for India’s biopharmaceutical sector, Pune-based startup PharmNXT Biotech has acquired Defined Tubing Routing (DTR), a globally recognised player from Ireland, working in advanced bioprocess tubing solutions.
This move enables PharmNXT to access technology solutions related to single-use systems, strengthening its capacity to serve pharmaceutical and biopharma clients with more tailored and technically aligned offerings.
With the addition of DTR’s modular tubing systems, capable of supporting bioprocess volumes from 20 L to 500 L and custom spans up to 2.9 meters, PharmNXT significantly expands its engineering capabilities, faster turnaround, enhanced customisation, and stronger compliance.
DTR systems are increasingly being adopted in biopharmaceutical manufacturing, especially within single-use technology setups where efficient tubing management is critical. These systems help reduce operational risks by minimizing trip hazards and clearly outlining flow paths, thereby supporting safety and compliance.
“This is a defining moment for the Indian biopharmaceutical sector,” said Sachin Joshi, Founder and Managing Director at PharmNXT. “With this acquisition, PharmNXT will introduce an innovative range of new solutions for biopharmaceutical and pharmaceutical customers worldwide. DTR is an innovative solution to address issues related to single-use tubing management. DTR systems are designed to handle single-use tubing in pharmaceutical and biotech/biopharma facilities, ensuring proper routing, reducing errors, and enhancing the overall appearance of the facility.
PharmNXT’s acquisition comes at a time when global pharma companies are looking for robust, de-risked supply chains, making India not just a backup but a preferred partner in biotech infrastructure.
